AN
Anika Therapeutics, Inc.
ANIK · NASDAQ
$20.37 +0.42% (+$0.09)
1M -2.40%
Market Cap $272.6M
P/E Ratio -
Div. Yield -
ROE 2.70%
Bulios Fair Price
$15.75
22.7% downside
Current Price
$20.37
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ANIK is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
5/9Valuation
23 /100
Expensive P/S 2.26x
P/B 1.99x
P/FCF 485.07x
Growth
15 /100
Declining Book val. growth 20.50%
Rev. growth 0.30%
FCF growth N/A
Profitability
23 /100
Weak Net margin 3.14%
Op. margin 4.24%
FCF margin 0.47%
Quality
8 /100
Poor ROE 2.70%
ROA 2.06%
Asset turnover 0.66x
Debt
100 /100
Low Current ratio 4.48x
Net debt/EBITDA -5.56x
Debt/Equity 0.17x
Stability
31 /100
Unstable Rev. volatility 6.03%
EPS volatility 294.89%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ANIK
Online
Sector
Healthcare
Industry
Medical - Specialties
CEO
Stephen D. Griffin
Employees
235
Headquarters
Bedford
Upcoming events
04 NOV
Earnings
Upcoming earnings report